Volume 90%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Play/PauseSPACE
Increase Volume↑
Decrease Volume↓
Seek Forward→
Seek Backward←
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Seek %0-9
00:00
00:00
00:00
 

Chapters

Transcript

 
Download Unlock

SPEAKER: If they already have a stent placed, yes, they belong to this very high-risk patient group. So according to the guidelines, the LDL should be below 70. If it's not below 70, then you should do some additional modification of therapies, which might be increase in statin dose, adding ezetimibe, or if this is not sufficient, put them on PCSK9 inhibitor in addition to continuing the statin therapy.

Scan View
Video

If someone is more than 12 months out after an ACS event and currently has a stent, would you still consider them to be eligible for PCSK9 therapy to lower LDL-C and residual CV risk?

Get Credit

If someone is more than 12 months out after an ACS event and currently has a stent, would you still consider them to be eligible for PCSK9 therapyto lower LDL-C and residual CV risk?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Interventional Cardiologist's Perspective

Presenter

Andreas Zeiher, MD

Andreas Zeiher, MD

Chairman of Medicine Department of Cardiology, Angiology, and Nephrology J. W. Goethe University Frankfurt, Germany